Antonios Bayas, Ulrich Mansmann, Begum Irmak Ön, Verena S Hoffmann, Achim Berthele, Mark Mühlau, Markus C Kowarik, Markus Krumbholz, Makbule Senel, Verena Steuerwald, Markus Naumann, Julia Hartberger, Martin Kerschensteiner, Eva Oswald, Christoph Ruschil, Ulf Ziemann, Hayrettin Tumani, Ioannis Vardakas, Fady Albashiti, Frank Kramer, Iñaki Soto-Rey, Helmut Spengler, Gerhard Mayer, Hans Armin Kestler, Oliver Kohlbacher, Marlien Hagedorn, Martin Boeker, Klaus Kuhn, Stefan Buchka, Florian Kohlmayer, Jan S Kirschke, Lars Behrens, Hanna Zimmermann, Benjamin Bender, Nico Sollmann, Joachim Havla, Bernhard Hemmer
INTRODUCTION: In Multiple Sclerosis (MS), patients´ characteristics and (bio)markers that reliably predict the individual disease prognosis at disease onset are lacking. Cohort studies allow a close follow-up of MS histories and a thorough phenotyping of patients. Therefore, a multicenter cohort study was initiated to implement a wide spectrum of data and (bio)markers in newly diagnosed patients. METHODS: ProVal-MS (Prospective study to validate a multidimensional decision score that predicts treatment outcome at 24 months in untreated patients with clinically isolated syndrome or early Relapsing-Remitting-MS) is a prospective cohort study in patients with clinically isolated syndrome (CIS) or Relapsing-Remitting (RR)-MS (McDonald 2017 criteria), diagnosed within the last two years, conducted at five academic centers in Southern Germany...
March 7, 2024: Neurological research and practice